Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01262599 · ClinicalTrials.gov registry record · Phase 4

Use of Pulsed Electromagnetic Fields (PEMF) After Breast Reconstruction Surgery

A Phase 4 study, sponsored by Columbia University.

Completed
Registry status
Phase 4
Development phase
32
Enrollment target

NCT01262599: Completed Phase 4 study, sponsored by Columbia University.

NCT01262599 is a Phase 4 study that has completed, run by Columbia University. The registered enrollment target is 32 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01262599, a Phase 4 study, has completed, sponsored by Columbia University.

COMPLETED
Registry status
Phase 4
Development phase
32 participants
Enrollment target

Study Summary

Pedicled transverse rectus abdominus myocutaneous (TRAM) flaps are the most common post-mastectomy breast reconstructive surgeries that utilize the patient's tissue. The pedicled TRAM flap involves harvesting skin, fat, and muscle from the abdomen to create a new breast. TRAM flap complications include fat necrosis of the reconstructed breast, delayed wound healing, and abdominal bulge or hernia. Pain at the abdominal donor site is a major contributor to the need for four to five days of post-operative hospital stay. Pulsed electromagnetic field (PEMF) technologies have been useful as adjunctive therapy for the treatment of delayed union fractures, chronic wounds and post-operative pain. PEMF devices are economical and disposable, and can be incorporated unobtrusively in standard post-operative dressings. The investigators have recently reported, in a double-blind, placebo-controlled study on breast reduction, that post-op PEMF therapy produced a significant decrease in pain and pain medication use, along with a concomitant decrease in IL1-beta in the wound bed. The proposed study seeks to determine whether similar results will be obtained after a significantly more extensive surgical procedure, like the TRAM flap. Patients scheduled for pedicled TRAM flap breast reconstruction of a single breast immediately following mastectomy will be enrolled in this double-blind, placebo-controlled, randomized study. Subjects will be assigned to one of two groups: a treatment group with active PEMF devices and a placebo group with sham devices that deliver no PEMF. PEMF and sham devices will be taped over both the breast reconstruction and abdominal donor sites. Patients will keep the devices in place for their hospital stay and for a total of two weeks. The investigators hypothesize that subjects in the PEMF treatment group compared to placebo will have a faster reduction in pain, take less pain and nausea medications, have lower levels of IL1-beta in wound exudate, have a sho

Primary Outcome

We will record postoperative pain, as reported by the patient and quantified by a standardized visual analog scale (VAS), with written descriptions at 12 hours post-op and assess that pain level in comparison with previous timepoint pain levels, such as 1 hour post-op. The VAS pain scale ranges from 0 (no pain) to 10 (worst possible pain). Higher scores indicate more pain and lower scores indicate less pain. The mean VAS score at 12 hours is reported for each group, active or placebo.

Interventions

  • DEVICE Sham PEMF Device
  • DEVICE Ivivi Torino II PEMF Device

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2010-02
Est. Completion 2014-04
Phase Phase 4
Columbia University

958 total trials

What the finished NCT01262599 record still lists

NCT01262599 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 2 interventions - of which Sham PEMF Device is the first listed.

NCT01262599 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01262599 about?

NCT01262599 is a clinical study titled "Use of Pulsed Electromagnetic Fields (PEMF) After Breast Reconstruction Surgery". Pedicled transverse rectus abdominus myocutaneous (TRAM) flaps are the most common post-mastectomy breast reconstructive surgeries that utilize the patient's tissue. The pedicled TRAM flap involves harvesting skin, fat, and muscle from the abdomen to create a new breast. TRAM flap complications incl...

What is the current status of trial NCT01262599?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2010-02. Estimated completion is 2014-04.

What interventions are being tested in trial NCT01262599?

The interventions under investigation include: Sham PEMF Device (DEVICE), Ivivi Torino II PEMF Device (DEVICE).

Who is sponsoring clinical trial NCT01262599?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01262599's enrollment target sits among peer trials

32 1534th of 2000 higher than 457 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01262599, the US trial registry maintained by the National Library of Medicine. NCT01262599 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.